Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Butt

Showing results (291-300 of 309) with videos related to

Pageof 31
Sort By:
Circulation. Heart Failure|February 22, 2023
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort StudyNiklas Dyrby Johansen, Muthiah Vaduganathan, Deewa Zahir, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
JAMA Cardiology|June 18, 2025
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
JAMA Cardiology|April 26, 2023
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER TrialPardeep S Jhund, Brian L Claggett, Atefeh Talebi, et al.
Journal of Cardiac Failure|December 17, 2023
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Karola Jering, Rudolf A DE Boer, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
Journal of the American College of Cardiology|December 12, 2024
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
Pageof 31

Showing results (291-300 of 309) with videos related to

Sort By:
Pageof 31
Circulation. Heart Failure|February 22, 2023
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort StudyNiklas Dyrby Johansen, Muthiah Vaduganathan, Deewa Zahir, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
JAMA Cardiology|June 18, 2025
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
JAMA Cardiology|April 26, 2023
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER TrialPardeep S Jhund, Brian L Claggett, Atefeh Talebi, et al.
Journal of Cardiac Failure|December 17, 2023
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Karola Jering, Rudolf A DE Boer, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
Journal of the American College of Cardiology|December 12, 2024
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
Pageof 31